Consensus Alumis Inc.

Stocks

ALMS

US0223071020

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-20 EDT			5-day change	1st Jan Change
6.700 ^USD	+5.68%		+2.13%	-31.35%

10-09	Alumis Inc. Announces New Envudeucitinib Data From The ONWARD Phase 3 Clinical Program	CI
10-09	Alumis Says Phase 3 Data From Plaque Psoriasis Program Reiterate Treatment's Potential as 'Leading' Oral Therapy	MT

Evolution of the Average Target: Alumis Inc.

Evolution of the Target Price: Alumis Inc.

Changes in Analyst Recommendations: Alumis Inc.

831cb5ecb12c9a18620bc3eac92726ef.Hz8qXud1QmjiXzrQrMfKuIsbI0duWSlbo8KSTAZYeiQ.cHRJMoInCSSBKWuU9b_817pORBQ8Mx8emoWnAkEJMHNAd3MHni91PIE4Ag~2d60e32ccab4afeac0adf6b3f008675c

Analysts' recommendations: Alumis Inc.

09-03	Guggenheim Downgrades Alumis to Neutral From Buy	MT
09-02	Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says	MT
09-02	Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating	MT
09-02	HC Wainwright Upgrades Alumis to Buy From Neutral, Adjusts Price Target to $15 From $25	MT
05-19	Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating	MT
05-15	HC Wainwright Downgrades Alumis to Neutral From Buy	MT
03-30	Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says	MT
03-30	Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating	MT
03-11	Raymond James Initiates Alumis at Strong Buy With $46 Price Target	MT
02-25	Stifel Initiates Alumis at Buy With $44 Price Target	MT
01-21	Chardan Initiates Alumis at Buy With $37 Price Target	MT
25-07-25	Wells Fargo Initiates Alumis at Overweight With $17 Price Target	MT
25-05-15	Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating	MT
25-02-10	Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating	MT
25-01-30	Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target	MT
24-10-31	Baird Initiates Alumis at Outperform With $25 Price Target	MT
24-10-17	HC Wainwright Initiates Coverage on Alumis With Buy Rating, $30 Price Target	MT
24-07-23	Cantor Fitzgerald Initiates Alumis at Overweight	MT
24-07-23	Guggenheim Initiates Alumis at Buy With $32 Price Target	MT
24-07-23	Morgan Stanley Initiates Alumis at Overweight With $36 Price Target	MT
24-07-23	Leerink Partners Initiates Alumis at Outperform With $29 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALUMIS INC.					+390.93%
	WUXI APPTEC CO., LTD.					+30.97%
	LONZA GROUP AG					+13.23%
	ARGENX SE					+38.42%
	IQVIA HOLDINGS INC.					+13.19%
	BEONE MEDICINES AG					+17.91%
	REVOLUTION MEDICINES, INC.					+41.56%
	CELLTRION, INC.					+35.14%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+9.2%
	Average					+61.53%
	Weighted average by Cap.					+26.54%